Cargando…

Early Experience with the Biotronik Protego ICD Lead

Background: In the last decade, newer generation ICD leads have been developed based on mechanistic insides of priorly failing leads. The aim of our study was to assess the long-term performance and mechanisms of failure of the 2013-introduced Biotronik Protego ICD lead in a real-world population. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Seiler, Thomas, Grebmer, Christian, Hilfiker, Gabriela, Kobza, Richard, Berte, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736976/
https://www.ncbi.nlm.nih.gov/pubmed/36498645
http://dx.doi.org/10.3390/jcm11237070
_version_ 1784847169355776000
author Seiler, Thomas
Grebmer, Christian
Hilfiker, Gabriela
Kobza, Richard
Berte, Benjamin
author_facet Seiler, Thomas
Grebmer, Christian
Hilfiker, Gabriela
Kobza, Richard
Berte, Benjamin
author_sort Seiler, Thomas
collection PubMed
description Background: In the last decade, newer generation ICD leads have been developed based on mechanistic insides of priorly failing leads. The aim of our study was to assess the long-term performance and mechanisms of failure of the 2013-introduced Biotronik Protego ICD lead in a real-world population. Methods: All patients, who underwent implantation of a Protego ICD lead at the Heart Centre Lucerne (Lucerne, Switzerland) between November 2013 and March 2017, were followed up with semi-annual device-controls. The primary endpoint was defined as lead failure, secondary endpoints compromised all-cause death, (in)appropriate shocks and the need for reintervention. Results: A total of 64 patients (mean age 66.7 ± 8.7 years, 30% female) underwent implantation of a Protego ICD lead: 78% for primary prevention, 53% had underlying ischemic heart disease, and 40.6% had a dilated cardiomyopathy (DCM). Mean left ventricular ejection fraction (LVEF) was 32.6 ± 10.5%. A total of 24 patients were treated with cardiac resynchronization therapy (CRT), and their baseline LVEF improved from 27.8 ± 7.3% before to 39.8 ± 12.5 after implantation (p < 0.001). Mean time to follow-up was 5.5 ± 0.9 years. Overall, 14 patients (26.6%) suffered from at least one episode of sustained ventricular tachycardia; in total 10 patients (15.6%) died. Two patients experienced lead failure due to lead fracture after 5.5 and 5.7 years, which was clinically apparent by an abrupt rise in lead impedance (>2000 Ω) and by repetitive inappropriate shocks, respectively. Conclusions: In this retrospective observational study, the calculated annual lead failure rate of the Biotronik Protego ICD lead was 0.59% per patient—thus, the durability and long-term performance seem to be promising.
format Online
Article
Text
id pubmed-9736976
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97369762022-12-11 Early Experience with the Biotronik Protego ICD Lead Seiler, Thomas Grebmer, Christian Hilfiker, Gabriela Kobza, Richard Berte, Benjamin J Clin Med Article Background: In the last decade, newer generation ICD leads have been developed based on mechanistic insides of priorly failing leads. The aim of our study was to assess the long-term performance and mechanisms of failure of the 2013-introduced Biotronik Protego ICD lead in a real-world population. Methods: All patients, who underwent implantation of a Protego ICD lead at the Heart Centre Lucerne (Lucerne, Switzerland) between November 2013 and March 2017, were followed up with semi-annual device-controls. The primary endpoint was defined as lead failure, secondary endpoints compromised all-cause death, (in)appropriate shocks and the need for reintervention. Results: A total of 64 patients (mean age 66.7 ± 8.7 years, 30% female) underwent implantation of a Protego ICD lead: 78% for primary prevention, 53% had underlying ischemic heart disease, and 40.6% had a dilated cardiomyopathy (DCM). Mean left ventricular ejection fraction (LVEF) was 32.6 ± 10.5%. A total of 24 patients were treated with cardiac resynchronization therapy (CRT), and their baseline LVEF improved from 27.8 ± 7.3% before to 39.8 ± 12.5 after implantation (p < 0.001). Mean time to follow-up was 5.5 ± 0.9 years. Overall, 14 patients (26.6%) suffered from at least one episode of sustained ventricular tachycardia; in total 10 patients (15.6%) died. Two patients experienced lead failure due to lead fracture after 5.5 and 5.7 years, which was clinically apparent by an abrupt rise in lead impedance (>2000 Ω) and by repetitive inappropriate shocks, respectively. Conclusions: In this retrospective observational study, the calculated annual lead failure rate of the Biotronik Protego ICD lead was 0.59% per patient—thus, the durability and long-term performance seem to be promising. MDPI 2022-11-29 /pmc/articles/PMC9736976/ /pubmed/36498645 http://dx.doi.org/10.3390/jcm11237070 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Seiler, Thomas
Grebmer, Christian
Hilfiker, Gabriela
Kobza, Richard
Berte, Benjamin
Early Experience with the Biotronik Protego ICD Lead
title Early Experience with the Biotronik Protego ICD Lead
title_full Early Experience with the Biotronik Protego ICD Lead
title_fullStr Early Experience with the Biotronik Protego ICD Lead
title_full_unstemmed Early Experience with the Biotronik Protego ICD Lead
title_short Early Experience with the Biotronik Protego ICD Lead
title_sort early experience with the biotronik protego icd lead
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736976/
https://www.ncbi.nlm.nih.gov/pubmed/36498645
http://dx.doi.org/10.3390/jcm11237070
work_keys_str_mv AT seilerthomas earlyexperiencewiththebiotronikprotegoicdlead
AT grebmerchristian earlyexperiencewiththebiotronikprotegoicdlead
AT hilfikergabriela earlyexperiencewiththebiotronikprotegoicdlead
AT kobzarichard earlyexperiencewiththebiotronikprotegoicdlead
AT bertebenjamin earlyexperiencewiththebiotronikprotegoicdlead